Tabula Rasa HealthCare (TRHC) Research Coverage Started at William Blair

William Blair initiated coverage on shares of Tabula Rasa HealthCare (NASDAQ:TRHC) in a research note issued to investors on Monday, December 11th, Marketbeat.com reports. The brokerage issued an outperform rating on the stock.

Several other brokerages have also issued reports on TRHC. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a strong-buy rating to a hold rating in a report on Friday, November 10th. BidaskClub lowered shares of Tabula Rasa HealthCare from a strong-buy rating to a buy rating in a report on Wednesday, December 6th. First Analysis initiated coverage on shares of Tabula Rasa HealthCare in a research note on Wednesday, November 1st. They set an overweight rating and a $41.00 price target on the stock. Piper Jaffray Companies reiterated an overweight rating and set a $35.00 price target on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Finally, ValuEngine upgraded shares of Tabula Rasa HealthCare from a sell rating to a hold rating in a research note on Saturday, September 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $29.00.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) traded up $1.20 during mid-day trading on Monday, hitting $29.25. 155,749 shares of the stock traded hands, compared to its average volume of 149,450. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73. The firm has a market cap of $500.66, a PE ratio of -117.00, a price-to-earnings-growth ratio of 37.40 and a beta of 3.20. Tabula Rasa HealthCare has a 1 year low of $11.59 and a 1 year high of $36.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. The firm had revenue of $33.27 million for the quarter, compared to analysts’ expectations of $31.76 million. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS. analysts expect that Tabula Rasa HealthCare will post 0.03 EPS for the current fiscal year.

In related news, Director Bruce Luehrs sold 269,000 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $25.85, for a total value of $6,953,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total value of $213,440.00. The disclosure for this sale can be found here. Insiders sold 1,099,180 shares of company stock valued at $28,435,203 over the last ninety days. 45.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY boosted its holdings in shares of Tabula Rasa HealthCare by 3.4% in the third quarter. Paradigm Capital Management Inc. NY now owns 80,000 shares of the company’s stock valued at $2,139,000 after acquiring an additional 2,644 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of Tabula Rasa HealthCare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after acquiring an additional 4,232 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Tabula Rasa HealthCare by 79.8% in the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock valued at $341,000 after acquiring an additional 5,668 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Tabula Rasa HealthCare by 60.2% in the second quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock valued at $248,000 after acquiring an additional 6,200 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Tabula Rasa HealthCare by 47.2% in the second quarter. Bank of New York Mellon Corp now owns 19,412 shares of the company’s stock valued at $293,000 after acquiring an additional 6,228 shares during the period. 31.85% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Tabula Rasa HealthCare (TRHC) Research Coverage Started at William Blair” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.truebluetribune.com/2018/01/03/tabula-rasa-healthcare-trhc-now-covered-by-analysts-at-william-blair-3.html.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply